Sequel Pharmaceuticals
Total Raised
$24.4MInvestors Count
5Deal Terms
2Funding, Valuation & Revenue
4 Fundings
Sequel Pharmaceuticals's latest funding round was a Dead for on December 16, 2015.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/16/2015 | Dead | Dead | 1 | |||
9/20/2010 | Unattributed VC | |||||
8/10/2009 | Series B | |||||
9/17/2007 | Series A |
Date | 12/16/2015 | 9/20/2010 | 8/10/2009 | 9/17/2007 |
|---|---|---|---|---|
Round | Dead | Unattributed VC | Series B | Series A |
Amount | ||||
Investors | Dead | |||
Valuation | ||||
Revenue | ||||
Sources | 1 |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
Sequel Pharmaceuticals Deal Terms
2 Deal Terms
Sequel Pharmaceuticals's deal structure is available for 2 funding rounds, including their Series B from August 10, 2009.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Sequel Pharmaceuticals Investors
5 Investors
Sequel Pharmaceuticals has 5 investors. Skyline Ventures invested in Sequel Pharmaceuticals's Unattributed VC funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/17/2007 | 9/20/2010 | 3 Series B, Series A (2007), Unattributed VC (2010) | Venture Capital | California | ||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | New Jersey |
First funding | 9/17/2007 | ||||
|---|---|---|---|---|---|
Last Funding | 9/20/2010 | ||||
Investor | |||||
Rounds | 3 Series B, Series A (2007), Unattributed VC (2010) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | California | California | California | California | New Jersey |
Compare Sequel Pharmaceuticals to Competitors
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.
Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).
Piedmont is a specialty pharmaceutical company focused on human and animal health therapeutics with expertise in parasitology and drug delivery systems.
Kytogenics is a medical device company. It had developed the Nocc Hydrophilic Wound Dressing.Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery patented platform technology.
Terapio is a biopharmaceutical company specializing in the development of a pipeline of therapies based on the transport protein, RLIP76.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.